AstraZeneca PLC
http://www.astrazeneca.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AstraZeneca PLC
Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies
Early-stage companies pioneering new modalities discussed the future of cardiometabolic therapy and partnering with big pharma at the LSX conference in London.
A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up
The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.
US FTC Targets Pharma Patent Abuse: What You Need to Know
The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Aviron
- Cellective Therapeutics, Inc.
- Definiens
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Medimmune
- Novexel
- Neogene Therapeutics, Inc.
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- TeneoTwo, Inc.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice